Understand · Treat · Recover
Immunotherapy and Targeted Therapy
These treatments work in different ways and have specific eligibility requirements. They are not interchangeable or automatically suitable for every patient.
For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.
This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.
Chapter 15 of 20
HER2-directed treatment
Trastuzumab blocks HER2 signalling and is combined with chemotherapy in eligible HER2-positive advanced adenocarcinoma. Heart function monitoring is important. KEYNOTE-811 supports adding pembrolizumab in the appropriate HER2-positive, PD-L1 CPS ≥1 first-line population. Trastuzumab deruxtecan, or T-DXd, is an antibody–drug conjugate: an HER2-directed antibody delivers a cytotoxic payload. It is used after prior trastuzumab-based treatment in eligible disease, with current HER2 status and local indications considered.
Zanidatamab and tislelizumab
Zanidatamab binds two sites on HER2; tislelizumab is a PD-1 inhibitor. HERIZON-GEA-01 supported the August 2026 US approval of zanidatamab plus chemotherapy and tislelizumab for HER2 IHC 3+ or IHC 2+/ISH-positive advanced gastroesophageal adenocarcinoma. Without tislelizumab, the zanidatamab–chemotherapy indication is limited to IHC 3+. Diarrhea, cardiac dysfunction and infusion reactions require attention, alongside immune toxicities when tislelizumab is included. The trial comparator was trastuzumab plus chemotherapy, so it does not establish a direct comparison against every modern HER2–immunotherapy regimen.
Checkpoint inhibitors
Nivolumab and pembrolizumab help the immune system recognise cancer by blocking PD-1. CheckMate 649 and KEYNOTE-859 established roles with chemotherapy in advanced adenocarcinoma. Benefit is not uniform across PD-L1 groups and is generally more compelling at higher CPS; MSI-high/dMMR is a separate important predictor. Current national labels may restrict low-CPS use. Durvalumab blocks PD-L1 and has a specific perioperative FLOT-based role where approved.
CLDN18.2 and blood-vessel targeting
Zolbetuximab targets CLDN18.2 in eligible HER2-negative advanced gastric/GEJ adenocarcinoma. SPOTLIGHT used mFOLFOX6 and GLOW used CAPOX; both supported improved outcomes in the selected population. Nausea, vomiting and infusion reactions need proactive management. Ramucirumab targets VEGFR2, a blood-vessel growth pathway, and is commonly combined with paclitaxel after progression. It does not require a tumour VEGFR test for routine selection.
Side effects that must be recognised early
- Immunotherapy can inflame bowel, lungs, liver, thyroid, pituitary, adrenal glands, kidneys or other organs. New diarrhea, cough, breathlessness, severe weakness, headache or jaundice requires prompt contact—even after treatment has stopped.
- T-DXd can cause interstitial lung disease/pneumonitis, sometimes serious or fatal. New cough, fever or breathlessness needs urgent assessment before the next dose.
- Ramucirumab can cause hypertension, protein in urine, bleeding, impaired wound healing and rare perforation. Surgery and bleeding risk require careful planning.
- HER2 therapies and chemotherapy can also cause low counts, nausea and other toxicities; monitoring is drug-specific.
What pivotal studies do—and do not—show
Trials compare defined regimens in selected groups. DESTINY-Gastric01 supported T-DXd in previously treated HER2-positive disease; DESTINY-Gastric02 added Western patient evidence; DESTINY-Gastric04 directly compared second-line T-DXd with ramucirumab–paclitaxel after trastuzumab and supported a survival advantage. These results do not justify use in HER2-negative disease or automatic application to esophageal squamous cancer.
Research and access
New antibody–drug conjugates, FGFR2b-directed drugs and CLDN18.2 cell therapies are being studied. A promising mechanism is not the same as proven benefit or a national approval. Ask whether treatment is standard, off-label or a clinical trial, what alternatives exist and which costs and visits are expected. Never stop steroids or other essential medicines without the team’s advice.
Key takeaways
Know the exact target, line of treatment and urgent toxicity signs for each drug.
Frequently asked questions
Is immunotherapy always easier than chemotherapy?
No. Its toxicities differ and can occasionally be severe or long-lasting.
Does a high CPS guarantee response?
No. It helps estimate benefit for particular treatments.
Is zolbetuximab suitable for any CLDN18 stain?
No. The validated assay, threshold, HER2 status and treatment setting matter.
Can T-DXd be given without prior trastuzumab?
The established gastric/GEJ indication is after a prior trastuzumab-based regimen; other uses need specific evidence and approval.
Should cough during T-DXd wait until the next visit?
No. Contact the team promptly because lung inflammation must be excluded.
Are approvals the same worldwide?
No. National labels, reimbursement and availability differ.
References and further reading
- CAP / ASCP / ASCO · HER2 testing guideline
- FDA · KEYNOTE-811 / pembrolizumab with trastuzumab, CPS ≥1 (2025)
- CheckMate 649 · Randomized trial, Lancet (2021)
- KEYNOTE-859 · Randomized trial, Lancet Oncology (2023)
- FDA · Zolbetuximab / SPOTLIGHT and GLOW (2024)
- DESTINY-Gastric01 · NEJM (2020)
- DESTINY-Gastric02 · Lancet Oncology (2023)
- DESTINY-Gastric04 · Randomized trial, NEJM (2025)
- Lilly · Ramucirumab prescribing information
- FDA · Perioperative durvalumab with FLOT, 25 November 2025
- FDA · Zanidatamab / tislelizumab, HERIZON-GEA-01, 25 August 2026
- DailyMed · Current nivolumab prescribing information